|
Market Closed -
OTC Markets
03:03:16 11/09/26 am AEST
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | -.--% |
|
-.--% | -99.80% |
| Market Cap | 1.3M 1.16M 1.07M 975K 1.83M 123M 1.86M 12.93M 5.09M 64.7M 4.89M 4.79M 205M | P/E 2023 |
-2.13x | P/E 2024 | -2.52x |
|---|---|---|---|---|---|
| Enterprise Value | 7.55M 6.74M 6.22M 5.65M 10.6M 715M 10.76M 74.91M 29.51M 375M 28.34M 27.74M 1.19B | EV / Sales 2023 |
394,366,816x | EV / Sales 2024 | 171,944,593x |
| Free-Float |
100% | Yield 2023 * |
-
| Yield 2024 | - |
| Current year | 0 | 0.01 | |
| 1 year | 0 | 0.01 | |
| 3 years | 0 | 0.25 | |
| 5 years | 0 | 2.15 | |
| 10 years | 0 | 4.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | - | - | |
Radka Milanova
CTO | Chief Tech/Sci/R&D Officer | 71 | - |
James Smeeding
PRN | Corporate Officer/Principal | - | 02/05/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | - | |
James Smeeding
BRD | Director/Board Member | - | 02/05/2020 |
Abdul Nnyenje
BRD | Director/Board Member | - | 21/10/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 25/4/23 | Buy | Director | 80,000 | 0.0824% | ||
| 22/9/20 | Buy | Chief Executive Officer | 10,000 | 0.0118% | ||
| 22/9/20 | Other | Chief Executive Officer | 0 | 0% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -.--% | - | - | 117 | ||
| +2.83% | +4.40% | +60.84% | +123.50% | 1,165B | ||
| +3.81% | +5.66% | +38.70% | +74.91% | 645B | ||
| +0.14% | +0.63% | +24.71% | +95.03% | 504B | ||
| -0.40% | +3.06% | +43.89% | +64.51% | 380B | ||
| -1.76% | +1.41% | +68.06% | +43.41% | 363B | ||
| -0.47% | +2.95% | +22.83% | +51.93% | 297B | ||
| -1.75% | +2.64% | +2.22% | +26.48% | 269B | ||
| +2.04% | +3.05% | +51.12% | +60.42% | 237B | ||
| +2.36% | -0.11% | +29.42% | +102.04% | 195B | ||
| Average | -0.29% | +2.29% | +37.98% | +71.36% | 405.55B | |
| Weighted average by Cap. | -0.31% | +3.17% | +43.13% | +83.13% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 0.07 0.06 0.06 0.05 0.1 6.83 0.1 0.72 0.28 3.58 0.27 0.26 11.33 | 0.1 0.09 0.08 0.07 0.13 9.11 0.14 0.95 0.38 4.77 0.36 0.35 15.12 |
| Net income | -10.68M -9.53M -8.79M -7.99M -14.98M -1.01B -15.21M -106M -41.72M -530M -40.07M -39.21M -1.68B | -3.98M -3.55M -3.27M -2.97M -5.58M -377M -5.67M -39.44M -15.54M -197M -14.93M -14.61M -625M |
| Net Debt | 5.65M 5.04M 4.65M 4.23M 7.93M 535M 8.05M 56.07M 22.09M 280M 21.21M 20.76M 889M | 6.25M 5.58M 5.14M 4.67M 8.77M 592M 8.9M 61.98M 24.41M 310M 23.45M 22.95M 982M |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- ALID Stock
Select your edition
All financial news and data tailored to specific country editions
















